RHY.ASX: Half-Year Financial Report and Appendix 4D

Half-Year Financial Report and Appendix 4D

Stock	RHYTHM Biosciences Ltd (RHY.ASX)
Release Time	18 Feb 2026, 2:14 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Rhythm Biosciences reports half-year financial results

Key Points

ColoSTAT® product moves from development to commercialisation
geneType™ platform expands with new partnerships and scientific validation
Successful $3.75 million capital raise strengthens balance sheet

Full Summary

Rhythm Biosciences Limited reported a loss of $2.26 million for the half-year ended 31 December 2025, reflecting continued investment in commercialisation activities across both the ColoSTAT® and geneType™ platforms. The period marked a pivotal transition for ColoSTAT®, with the product moving from development into active commercialisation following the securing of ISO 15189:2022 laboratory accreditation. The geneType™ genetic risk assessment platform also demonstrated strong commercial and scientific momentum, with two strategic distribution partnerships secured and a collaboration with Memorial Sloan Kettering Cancer Center. The company successfully completed a $3.75 million capital raising, strengthening its balance sheet as it enters its commercial phase.